ORKA

SEC source: 0000907654-26-000084 · form4.xml · derivative · entry 2

Edwards Larry Todd · CIK 0001994805 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-08-23

F2 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on August 24, 2027, and vests as to 1/48 of the underlying shares monthly thereafter.

SEC source: 0000907654-26-000084 · form4.xml · nonDerivative · entry 1

Edwards Larry Todd · CIK 0001994805 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

F1 · shares: The grant vests as to 1/4 of the shares on September 14, 2027, with the balance vesting in 12 equal quarterly installments thereafter.

SEC source: 0000907654-26-000079 · form4.xml · derivative · entry 8

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,492

Underlying: Common Stock · 3,500 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

SEC source: 0000907654-26-000079 · form4.xml · derivative · entry 7

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 197,063

Underlying: Common Stock · 3,500 shares

Expires 2034-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

SEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 6

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,718

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.34 to $112.86, inclusive.

SEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 5

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,198

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.34 to $112.33, inclusive.

SEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 4

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,518

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.27 to $111.00, inclusive.

SEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 3

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,818

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.05 to $110.04, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

SEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 2

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000079 · form4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000077 · form4.xml · derivative · entry 10

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,500

Underlying: Common Stock · 42,000 shares

Expires 2035-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

SEC source: 0000907654-26-000077 · form4.xml · derivative · entry 9

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,996

Underlying: Common Stock · 10,000 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.

SEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 8

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,034

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.66 to $111.22, inclusive.

SEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 7

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,881

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.58 to $110.55, inclusive.

SEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 6

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,074

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.56 to $109.51, inclusive.

SEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 5

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,274

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.54 to $108.52, inclusive.

SEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 4

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,970

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.54 to $107.53, inclusive.

SEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 3

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,404

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.53 to $106.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.

SEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 2

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,034

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000077 · form4.xml · nonDerivative · entry 1

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,034

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000075 · form4.xml · derivative · entry 9

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,792

Underlying: Common Stock · 1,458 shares

Expires 2036-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

SEC source: 0000907654-26-000075 · form4.xml · derivative · entry 8

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,917

Underlying: Common Stock · 8,542 shares

Expires 2035-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

SEC source: 0000907654-26-000075 · form4.xml · nonDerivative · entry 7

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,312

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.24 to $108.71, inclusive.

SEC source: 0000907654-26-000075 · form4.xml · nonDerivative · entry 6

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,670

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.20 to $108.19, inclusive.

SEC source: 0000907654-26-000075 · form4.xml · nonDerivative · entry 5

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,812

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.11 to $107.07, inclusive.

SEC source: 0000907654-26-000075 · form4.xml · nonDerivative · entry 4

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,080

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.11 to $106.08, inclusive.

SEC source: 0000907654-26-000075 · form4.xml · nonDerivative · entry 3

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,212

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.05 to $104.99, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.

SEC source: 0000907654-26-000075 · form4.xml · nonDerivative · entry 2

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,312

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000075 · form4.xml · nonDerivative · entry 1

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000073 · form4.xml · derivative · entry 8

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,992

Underlying: Common Stock · 3,500 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

SEC source: 0000907654-26-000073 · form4.xml · derivative · entry 7

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 200,563

Underlying: Common Stock · 3,500 shares

Expires 2034-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

SEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 6

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,718

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.25 to $87.26, inclusive.

SEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 5

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,018

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.21 to $87.04, inclusive.

SEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 4

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,821

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.21 to $86.20, inclusive.

SEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 3

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,318

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.87 to $84.57, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

SEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 2

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000073 · form4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000071 · form4.xml · derivative · entry 8

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,250

Underlying: Common Stock · 1,458 shares

Expires 2036-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

SEC source: 0000907654-26-000071 · form4.xml · derivative · entry 7

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 101,459

Underlying: Common Stock · 8,541 shares

Expires 2035-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

SEC source: 0000907654-26-000071 · form4.xml · nonDerivative · entry 6

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,312

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.56 to $85.69, inclusive.

SEC source: 0000907654-26-000071 · form4.xml · nonDerivative · entry 5

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,612

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.54 to $85.50, inclusive.

SEC source: 0000907654-26-000071 · form4.xml · nonDerivative · entry 4

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,268

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.54 to $84.53, inclusive.

SEC source: 0000907654-26-000071 · form4.xml · nonDerivative · entry 3

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,011

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.49 to $83.37, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

SEC source: 0000907654-26-000071 · form4.xml · nonDerivative · entry 2

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,311

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000071 · form4.xml · nonDerivative · entry 1

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,853

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-26-080009 · tm2619616-1_4seq1.xml · derivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest III L.P. · CIK 0002009690 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 94,497

Underlying: Common Stock · 3,553,410 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-26-080009 · tm2619616-1_4seq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest III L.P. · CIK 0002009690 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 1,131,954

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-26-080009 · tm2619616-1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest III L.P. · CIK 0002009690 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 4,685,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000907654-26-000069 · form4.xml · derivative · entry 5

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,996

Underlying: Common Stock · 5,000 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.

SEC source: 0000907654-26-000069 · form4.xml · nonDerivative · entry 4

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 236,384

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.40 to $95.51, inclusive.